Consensus Collegium Pharmaceutical, Inc.

Stocks

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2026-11-02 pm EST			5-day change	1st Jan Change
23.68 ^USD	-0.50%		+2.02%	-48.86%

Oct. 29	Collegium Pharmaceutical, Inc. And Boston Legacy FC Expand Partnership To Support Neurodivergent Children And Families Across Massachusetts	CI
Oct. 19	Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million	MT

Evolution of the Average Target: Collegium Pharmaceutical, Inc.

Evolution of the Target Price: Collegium Pharmaceutical, Inc.

Changes in Analyst Recommendations: Collegium Pharmaceutical, Inc.

da96e8d60bbfd4de424b45ab74.mXTOYqaLk7lCyv7DPieX764VV5WnvX_le8qQeC9SFxw.0hORUtXuodgDiKnudHH7iPx7EOHg5T2SOavoFhZgQUWhEoNR9sHi-hWgzg~e9462d64181fc846912c71509deb16e4

Analysts' recommendations: Collegium Pharmaceutical, Inc.

Oct. 09	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says	MT
Sep. 23	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says	MT
Sep. 23	Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target	MT
Sep. 09	Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target	MT
Sep. 09	Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating	MT
Feb. 10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
Jan. 07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
Dec. 09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
Nov. 07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
25-08-08	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
25-08-07	Collegium Pharma Q2 revenue beats analyst expectations	RE
25-01-10	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
24-08-09	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
24-07-30	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
24-06-07	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
24-05-10	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
24-05-10	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
24-02-26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
24-02-26	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
24-01-04	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
24-01-04	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
23-08-25	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
23-05-02	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
23-01-05	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
22-11-04	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COLLEGIUM PHARMACEUTICAL, INC.					+106.93%
	ELI LILLY AND COMPANY					+1.13%
	JOHNSON & JOHNSON					+3.27%
	ABBVIE INC.					+5.79%
	ROCHE HOLDING AG					-0.68%
	MERCK & CO., INC.					+7.78%
	NOVARTIS AG					-4.27%
	ASTRAZENECA PLC					+14.77%
	AMGEN INC.					-14.64%
	GILEAD SCIENCES, INC.					+1.27%
	Average					+12.14%
	Weighted average by Cap.					+2.06%